LT3423087T - Kompleksinė priešvėžinė terapija - Google Patents
Kompleksinė priešvėžinė terapijaInfo
- Publication number
- LT3423087T LT3423087T LTEPPCT/EP2017/055093T LTEP2017055093T LT3423087T LT 3423087 T LT3423087 T LT 3423087T LT EP2017055093 T LTEP2017055093 T LT EP2017055093T LT 3423087 T LT3423087 T LT 3423087T
- Authority
- LT
- Lithuania
- Prior art keywords
- combination therapy
- against cancer
- therapy against
- cancer
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603805.1A GB201603805D0 (en) | 2016-03-04 | 2016-03-04 | Combination |
| GBGB1610018.2A GB201610018D0 (en) | 2016-06-08 | 2016-06-08 | Combination |
| PCT/EP2017/055093 WO2017149150A1 (en) | 2016-03-04 | 2017-03-03 | Combination therapy against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3423087T true LT3423087T (lt) | 2024-01-25 |
Family
ID=58231605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2017/055093T LT3423087T (lt) | 2016-03-04 | 2017-03-03 | Kompleksinė priešvėžinė terapija |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190343940A1 (lt) |
| EP (2) | EP3423087B1 (lt) |
| JP (3) | JP2019507180A (lt) |
| DK (1) | DK3423087T3 (lt) |
| ES (1) | ES2965009T3 (lt) |
| FI (1) | FI3423087T3 (lt) |
| HR (1) | HRP20240052T1 (lt) |
| HU (1) | HUE064857T2 (lt) |
| LT (1) | LT3423087T (lt) |
| PT (1) | PT3423087T (lt) |
| SI (1) | SI3423087T1 (lt) |
| WO (1) | WO2017149150A1 (lt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| HRP20231579T1 (hr) | 2016-12-07 | 2024-03-15 | Agenus Inc. | Anti-ctla-4 antitijela i postupci njihove upotrebe |
| AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
| BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
| WO2019102265A1 (en) * | 2017-11-23 | 2019-05-31 | Theraphage Inc. | Peptide displaying bacteriophage nanoparticles and related compositions and methods |
| US20200299401A1 (en) * | 2017-11-24 | 2020-09-24 | Io Biotech Aps | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
| CN111971308A (zh) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| KR102653960B1 (ko) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | 암 치료를 위한 면역체크포인트 억제제의 병용 요법 |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| BR112023017582A2 (pt) | 2021-03-05 | 2023-12-05 | Univ Basel | Composições para o tratamento de doenças ou condições associadas ao ebv |
| GB202103673D0 (en) * | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4340948A1 (en) * | 2021-05-17 | 2024-03-27 | Wisconsin Alumni Research Foundation (WARF) | Synthetic protein for inducing immune tolerance |
| TW202345864A (zh) * | 2022-02-18 | 2023-12-01 | 美商現代公司 | 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途 |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| EP3320912B1 (en) * | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| ES2918580T3 (es) | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| KR20220153677A (ko) * | 2014-02-04 | 2022-11-18 | 인사이트 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합 |
| JP6652557B2 (ja) * | 2014-05-30 | 2020-02-26 | ヴェンタナ メディカル システムズ， インク． | Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ |
-
2017
- 2017-03-03 PT PT177090388T patent/PT3423087T/pt unknown
- 2017-03-03 JP JP2018546596A patent/JP2019507180A/ja active Pending
- 2017-03-03 HU HUE17709038A patent/HUE064857T2/hu unknown
- 2017-03-03 DK DK17709038.8T patent/DK3423087T3/da active
- 2017-03-03 FI FIEP17709038.8T patent/FI3423087T3/fi active
- 2017-03-03 WO PCT/EP2017/055093 patent/WO2017149150A1/en active Application Filing
- 2017-03-03 EP EP17709038.8A patent/EP3423087B1/en active Active
- 2017-03-03 ES ES17709038T patent/ES2965009T3/es active Active
- 2017-03-03 HR HRP20240052TT patent/HRP20240052T1/hr unknown
- 2017-03-03 US US16/081,778 patent/US20190343940A1/en not_active Abandoned
- 2017-03-03 LT LTEPPCT/EP2017/055093T patent/LT3423087T/lt unknown
- 2017-03-03 EP EP23202447.1A patent/EP4316517A3/en active Pending
- 2017-03-03 SI SI201731444T patent/SI3423087T1/sl unknown
-
2021
- 2021-09-07 US US17/468,263 patent/US20220257741A1/en active Pending
-
2022
- 2022-02-25 JP JP2022027569A patent/JP7417645B2/ja active Active
-
2024
- 2024-01-05 JP JP2024000506A patent/JP2024045180A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3423087A1 (en) | 2019-01-09 |
| FI3423087T3 (fi) | 2023-12-15 |
| JP2022068348A (ja) | 2022-05-09 |
| EP4316517A3 (en) | 2024-05-29 |
| US20220257741A1 (en) | 2022-08-18 |
| JP7417645B2 (ja) | 2024-01-18 |
| US20190343940A1 (en) | 2019-11-14 |
| EP4316517A2 (en) | 2024-02-07 |
| SI3423087T1 (sl) | 2024-03-29 |
| HRP20240052T1 (hr) | 2024-03-29 |
| PT3423087T (pt) | 2023-12-28 |
| WO2017149150A1 (en) | 2017-09-08 |
| ES2965009T3 (es) | 2024-04-10 |
| HUE064857T2 (hu) | 2024-04-28 |
| EP3423087B1 (en) | 2023-11-15 |
| JP2024045180A (ja) | 2024-04-02 |
| JP2019507180A (ja) | 2019-03-14 |
| DK3423087T3 (da) | 2023-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263521A (en) | Combination therapy | |
| IL254705A0 (en) | Combination therapy for cancer | |
| IL271946A (en) | Combination for cancer treatment | |
| IL262661B (en) | Combined treatment for cancer | |
| HUE064857T2 (hu) | Kombinációs terápia a rák ellen | |
| HK1258319A1 (zh) | 癌症療法 | |
| IL263123A (en) | Cancer treatments | |
| IL265406B (en) | combined treatment | |
| EP3256115A4 (en) | COMBINATION CANCER THERAPY | |
| HK1251794A1 (zh) | 癌症治療 | |
| GB201604318D0 (en) | Combination therapy | |
| GB201604316D0 (en) | Combination therapy | |
| GB201519734D0 (en) | Cancer therapy | |
| IL265340A (en) | Combination therapy | |
| GB201704909D0 (en) | Cancer therapy | |
| GB201609735D0 (en) | Combination therapy | |
| GB201603653D0 (en) | Combination Therapy | |
| HK1254687A1 (zh) | 用於癌症的聯合療法 | |
| GB201711855D0 (en) | Cancer therapy | |
| HRP20210383T8 (hr) | Kombinirana terapija za rak | |
| GB201711250D0 (en) | Cancer therapy | |
| GB201710198D0 (en) | Cancer therapy | |
| GB201706046D0 (en) | Cancer therapy | |
| GB201700772D0 (en) | Cancer therapy | |
| GB201601248D0 (en) | Cancer therapy |